

AMENDMENTS TO THE SPECIFICATION

Please amend the specification at Page 1, last paragraph, as follows:

It has surprisingly been found that novel peptides of the general formula:

B1
Gly-Ser-Ser(Octanoyl)-Phe-A where A is -OH, NH₂ (SEQ ID NO:1), ~~Leu-Ser-Pro-Glu-X~~,
Leu-Ser-Pro-Glu-B (SEQ ID NO: 2), or -Ala-Lys-Leu-Gln-Pro-Arg-B (SEQ ID NO: 3)
where B is -OH or NH₂ decrease, rather than increase the level of circulating GH in
mammals, presumably because these peptides antagonize the effect of the ghrelins. For this
reason, these peptides are of value in normalizing or reducing elevated levels of growth
hormone such as those found in acromegalic patients or in other tumor related overproduction
GH.

Please amend the specification at Page 2, Example 1, as follows:

--By solid phase synthesis the following peptide was prepared:

B2
Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu (SEQ ID NO:2)--

Please amend the specification at Page 3, Example 2, as follows:

--By the same method of Example 1, the following tetradecapeptide was

B3
prepared: Gly-Ser-Ser(Octanoyl)-Phe-Leu-Ser-Pro-Glu-Ala-Lys-Leu-Gln-Pro-Arg (SEQ ID
NO:4)--

Please amend the specification at Page 4, Example 3, as follows:

--By the same method of Example 1, the following peptide was prepared:

B4
Gly-Ser-Ser(Octanoyl)-Phe (SEQ ID NO:1)--